Study:
Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine and Irinotecan (VI) for Patients With Intermediate-Risk Rhabdomyosarcoma (RMS)
Rationale:
Drugs used in chemotherapy, such as vincristine, dactinomycin, cyclophosphamide,
and irinotecan, work in different ways to stop the growth of tumor cells, either by killing
the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to
kill tumor cells. Giving combination chemotherapy together with radiation therapy may kill
more tumor cells. It is not yet known which combination chemotherapy regimen is more
effective when given together with radiation therapy in treating patients with
rhabdomyosarcoma.
Purpose:
This randomized phase III trial is studying two different combination chemotherapy
regimens to compare how well they work when given together with radiation therapy in
treating patients with newly diagnosed rhabdomyosarcoma.
Study Status: Recruiting
Recruiting:
Clinical Trials Office - Cleveland Clinic Taussig Cancer Cente 866-223-8100
| Condition |
Intervention |
Phase |
|
Sarcoma |
Biological: dactinomycin
Drug: cyclophosphamide
Drug: irinotecan hydrochloride
Drug: vincristine sulfate
Radiation: radiation therapy |
Phase 3 |
Verified by
Children`s Oncology Group
November, 2012
Sponsored by: Children`s Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00354835
Study Type: Interventional
Study Design: Allocation: Randomized, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Douglas Hawkins, MD., Study Chair
Geoffrey McCowage, MD.,
Leo Mascarenhas, MD.,